• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sucampo Pharmaceuticals to Present at the 10th Annual BIO CEO and Investor Conference

Posted on: Friday, 8 February 2008, 18:00 CST

Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP), a Bio Pharma company developing prostone-based therapies for age-related and other diseases, today announced that its chief executive officer, Ryuji Ueno, M.D., Ph.D., Ph.D, will present at the 10th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City at 1:15 p.m. (ET) on Tuesday, February 12, 2008. Dr. Ueno will provide a corporate overview, including a discussion of product development programs and recent corporate activities.

A webcast of this presentation will be available both live and by replay. A link to the live webcast will be available by logging on to the "For Investors" section of the Company's website, www.sucampo.com, and clicking "Webcasts & Presentations." A link to the archived version of the presentation also will be available on the Company's website.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a Bio Pharma company based in Bethesda, MD, focuses on the development and commercialization of drugs based on prostones, a class of novel endogenous bio-lipids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals' first product, AMITIZA(R) (lubiprostone), received marketing approval from the FDA in January 2006. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.

Source: Business Wire

More News in this Category